Skip to main content
Explore URMC

menu

Bladder Cancer: A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer (EV-201)

Research Question:
How does enfortumab vedotin affect patients with urothelial cancer?

Basic Study Information

Purpose:
If you choose to take part in this study, the study treatment cycle is 28-days. You will receive treatment with enfortumab vedotin on Day 1, 8, and 15 of each treatment cycle. Enfortumab vedotin is given as an infusion into a vein (over about 30 minutes).

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03219333?term=SGN22E-001&rank=1
Study Reference #: IGUB17080

Lead Researcher (Principal Investigator)

Lead Researcher: Chunkit Fung

Study Contact Information

Study Coordinator: Ayesha Khan
Phone: (585) 275-3351
Email: Ayesha_Khan@URMC.Rochester.edu

Additional Study Details

Return to Search